Skip to content

Exercise Therapy in Mental Disorders-study

Exercise Therapy in Mental Disorders-study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06313918
Enrollment
50
Registered
2024-03-15
Start date
2023-09-27
Completion date
2026-09-26
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Schizophrenia and Related Disorders

Keywords

Exercise therapy, Effectiveness

Brief summary

The study will compare standard high-intensity training with brief high-intensity training in people with schizophrenia-spectrum or bipolar disorder. The overall aim is to determine which of the two is superior in a long-term perspective.

Detailed description

Background: Patients with severe mental disorders (SMD), including schizophrenia spectrum and bipolar disorders, frequently experience suboptimal treatment effectiveness resulting in disabling residual symptoms and cognitive challenges, and have elevated mortality risk amounting to 15-20 years of shortened life expectancy compared to the general population. Cardiovascular disease (CVD) is a major contributor in this regard. Exercise in general improves cognitive functioning, negative symptoms, quality of life, and reduces the risk of CVD. High intensity training (HIT) has been shown to be feasible for persons with SMD, but attrition and noncompliance are substantial and likely to limit the effectiveness of HIT. A less strenuous HIT could increase adherence to the intervention, which might compensate for a slightly lower efficacy compared to standard HIT. Our study will compare standard 4x4-min HIT to a 4-min single-bout HIT session, as well as explore exercise effects on basic processes in the body. Methods: Patients with schizophrenia spectrum and bipolar disorders are eligible for participation, and those included will be randomized to 26 weeks of either 1) Standard 4 x 4 min HIT at treadmill, or 2) Short 1 x 4 min HIT at treadmill. To reduce dropout, the intervention will usually be delivered in group format, and conducted under the supervision of a physical therapist in collaboration with a postdoctor. The research group has a stable staff with research nurses, biostatisticians and researchers that will secure the dayto- day conductance of the project, including psychometric assessments, drawing of and biobanking of blood, as well as data collection and storing. Measures: Mental and cognitive symptoms, quality of life, motivation, Peak oxygen uptake (V

Interventions

Please see information already included in the arm descriptions.

Sponsors

Haukeland University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Open label, two-arm, parallel group, randomised trial, to compare standard and short HIT during 26 weeks of supervised exercise. The group will receive comprehensive follow-up to be able to carry out the 26 weeks exercise intervention program. Outcome measures will be taken at; baseline (T0), 4 weeks (T1), 12 weeks (T2), 26 weeks (T3), and 52 weeks (T4) post randomisation.

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ICD-10 schizophrenia-spectrum disorder (F2) * ICD-10 bipolar disorder (F3) * Capacity to provide informed consent.

Exclusion criteria

* Contra-indication for exercise training and testing according to the American College of Sports Medicine specifications * Life threatening or terminal medical conditions * Not able to carry out intervention or test procedures * Current pregnancy * Mothers less than 6 months post-partum.

Design outcomes

Primary

MeasureTime frameDescription
Adherence26 weeksProportion (number and percent) of completers at 26 weeks.

Secondary

MeasureTime frameDescription
Change of the Calgary Depression Scale in Schizophrenia score4, 12, 26 and 52 weeks from baselineSymptoms of depression
Change of the Clinical Global Impression (CGI) score4, 12, 26 and 52 weeks from baselineOverall clinical state
Change of the Global Assessment of Funtioning (GAF) score4, 12, 26 and 52 weeks from baselineFunctioning
Change of quality of life (QOL10) score4, 12, 26 and 52 weeks from baselineQuality of life
Change of the International Physical Activity Questionaire (IPAQ) score4, 12, 26 and 52 weeks from baselinePhysical activity
Change of the Brief Assessment of Cognition in Schizophrenia (BACS) score4, 12, 26 and 52 weeks from baselineCognition
Change of the Behavioural Regulation in Exercise Questionaire (BREQ) score4, 12, 26 and 52 weeks from baselineMotivation
Change of the Difficulties in Emotion Regulation (DERS) score4, 12, 26 and 52 weeks from baselineEmotion regulation
Change in heart rate (beats per minute)4, 12, 26 and 52 weeks from baselineHeart rate variability
Change of the Simplified Negative and Positive Symptoms Interview (SNAPSI) score4, 12, 26 and 52 weeks from baselineSymptoms of psychosis
Change of level of inflammatory markers in blood4, 12, 26 and 52 weeks from baselineInflammation
Change of body weight (kilograms)4, 12, 26 and 52 weeks from baselineBody weight change
Change of hip- and waist circumference (centimetres)4, 12, 26 and 52 weeks from baselineChange of hip- and waist circumference
Change of serum glucose (mmol/L)4, 12, 26 and 52 weeks from baselineChange of serum glucose
Change of serum cholesterols (mmol/L)4, 12, 26 and 52 weeks from baselineChange of serum cholesterols
Change of serum triglyceride (mmol/L)4, 12, 26 and 52 weeks from baselineChange of serum triglyceride (mmol/L)
Change of gene expression4, 12, 26 and 52 weeks from baselineRNA
Change of methylation of DNA4, 12, 26 and 52 weeks from baselineEpigenetic changes
Change of the Young Mania Rating Scale (YMRS) score4, 12, 26 and 52 weeks from baselineSymptoms of mania
Change of maximal oxygene extraction (VO2max)4, 12, 26 and 52 weeks from baselineAerobic capacity

Countries

Norway

Contacts

Primary ContactErik Johnsen, PhD
erik.johnsen@helse-bergen.no004792456225
Backup ContactRune A Kroken, PhD
rune.andreas.kroken@helse-bergen.no004792095205

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026